ImmunoGen Revenue, Profits - IMGN Quarterly Income Statement

Add to My Stocks
$8.82 $0.22 (2.43%) IMGN stock closing price Sep 19, 2018 (Closing)

Stock analysis based on fundamentals means looking at financial statements in addition to the ImmunoGen stock price. In the income statement, an investor can check for important parameters like the topline or sales, the bottomline or profits, the basic EPS, dividends etc. When compared with the corresponding income statement from the past, the latest income statement shows how revenue has decreased from 19.82M to 9.29M and how operating and non operating activities have impacted the IMGN stock. The operating expenses as shown in the ImmunoGen profit and loss statement for 2018 Q2 total to $48.04M. This line item shows that the operating expenses has decreased compared with last year. Also check: ImmunoGen assets and ImmunoGen free cash flow.

View and download details of revenue and profits for ImmunoGen for latest & last 40 quarters.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
ImmunoGen Revenues or Net Sales
9.29M19.82M39.45M8.48M39.02M28.69M13.85M7.66M7.41M19.71M
Cost Of Goods Sold (COGS)----------
ImmunoGen Gross Profit
9.29M19.81M39.45M8.48M39.02M28.49M-87.37M7.66M7.42M19.71M
Research & Development Expense38.7M44.83M39.86M31.68M35.31M32.88M-217.06M32.9M38.66M36.09M
Selling General & Admin Expense9.34M11.72M9.46M7.9M8.83M8.5M-61.72M13.58M9.31M11.23M
Income Before Depreciation Depletion Amortization-38.75M-36.74M-9.85M-31.11M-5.13M-12.89M191.43M-38.83M-40.55M-27.61M
Depreciation Depletion Amortization----------
Non Operating Income-0.24M1.19M-0.02M-21.41M---1.22M--0.41M-
Interest Expense2.63M3.07M3.26M4.14M4.62M4.7M-31.26M6.16M4.97M4.97M
ImmunoGen Pretax Income
-41.62M-38.61M-13.13M-56.68M-8.86M-17.34M221.46M-44.73M-45.93M-31.92M
Provision for Income Taxes----------
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-41.62M-38.61M-13.12M-56.68M-8.87M-17.34M-34.15M-44.73M-44.76M-31.93M
Extraordinary Items & Discontinued Operations----------
ImmunoGen Profit/ Loss (Net Income)
-41.62M-38.61M-13.12M-56.68M-8.87M-17.34M-34.15M-44.73M-44.76M-31.93M
Average Shares used to compute Diluted EPS134.38M130.62M124.58M93M87.17M87.16M87.1M87.1M87.06M87.04M
Average Shares used to compute Basic EPS134.38M130.62M124.58M93M87.17M87.16M87.1M87.1M87.06M87.04M
Income Before Nonrecurring Items-40.94M-38.61M-12.39M-34.49M-8.87M-17.34M-34.15M-40.6M-44.76M-31.93M
Income from Nonrecurring Items-0.69M--0.72M-22.19M----4.13M--
ImmunoGen Earnings Per Share Basic Net
-0.31-0.30-0.11-0.61-0.10-0.20-0.39-0.51-0.51-0.37
ImmunoGen Earnings Per Share Diluted Net
-0.31-0.30-0.11-0.61-0.10-0.20-0.39-0.51-0.51-0.37
EPS Diluted Before Nonrecurring Items-0.30-0.30-0.10-0.37-0.10-0.20-0.39-0.46-0.51-0.37
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

It is very helpful to read a report on ImmunoGen stock analysis. An investor must check the following items in an income statement:

  • Revenue: This is the inflow that is generated from the sale of goods or services and is $9.29M for this quarter of 2018 Q2. Our ImmunoGen revenue chart gives a clear visual representation of how the topline or sales growth has been. Investors often invest only in those companies where the revenue is growing at a steady rate.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $-41.62M for ImmunoGen for 2018 Q2. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called the profit and loss statement. Apart from the IMGN income statement, one can check the ImmunoGen historical stock prices to check how the price has moved with time.

ImmunoGen Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
15.38
Dividend Yield
0%